Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Liquidia Corp (LQDA)

Liquidia Corp (LQDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 839,790
  • Shares Outstanding, K 76,414
  • Annual Sales, $ 17,490 K
  • Annual Income, $ -78,500 K
  • 60-Month Beta 0.32
  • Price/Sales 49.53
  • Price/Cash Flow N/A
  • Price/Book 10.03
Trade LQDA with:

Options Overview Details

View History
  • Implied Volatility 107.81% ( -0.21%)
  • Historical Volatility 48.83%
  • IV Percentile 80%
  • IV Rank 58.07%
  • IV High 151.36% on 11/07/23
  • IV Low 47.49% on 09/19/23
  • Put/Call Vol Ratio 1.68
  • Today's Volume 11,954
  • Volume Avg (30-Day) 4,189
  • Put/Call OI Ratio 0.84
  • Today's Open Interest 89,603
  • Open Int (30-Day) 63,001

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.35
  • Number of Estimates 4
  • High Estimate -0.26
  • Low Estimate -0.44
  • Prior Year -0.36
  • Growth Rate Est. (year over year) +2.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.68 +3.73%
on 07/19/24
13.24 -16.31%
on 07/16/24
-1.44 (-11.50%)
since 06/18/24
3-Month
10.68 +3.73%
on 07/19/24
15.19 -27.06%
on 06/03/24
-2.21 (-16.63%)
since 04/19/24
52-Week
5.71 +94.05%
on 10/19/23
16.99 -34.79%
on 03/22/24
+3.16 (+39.90%)
since 07/19/23

Most Recent Stories

More News
ANAVASI DIAGNOSTICS ANNOUNCES NEWLY ELECTED OUTSIDE BOARD OF DIRECTORS

/PRNewswire/ -- Anavasi Diagnostics ('Anavasi'), an NIH/RADx medical technology company focused on the development of novel molecular diagnostic testing,...

LQDA : 11.08 (+0.82%)
CYAN : 0.5800 (+0.17%)
Why Liquidia Stock Rocketed Nearly 21% Higher Today

Investors were obviously cheered by a round of insider buying.

LQDA : 11.08 (+0.82%)
UTHR : 329.16 (+0.15%)
Why Liquidia Shares Rose 18.4% on Monday

Optimism by the company regarding a patent ruling is encouraging investors.

LQDA : 11.08 (+0.82%)
UTHR : 329.16 (+0.15%)
Liquidia Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Company to host webcast and conference call today at 8:30 a.m. ET MORRISVILLE, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:...

LQDA : 11.08 (+0.82%)
Liquidia to Report Second Quarter 2022 Financial Results on August 11, 2022

MORRISVILLE, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its second quarter 2022...

LQDA : 11.08 (+0.82%)
Why Shares of MannKind Corporation Climbed 10.4% on Monday

The company is coming off an FDA approval for its second marketed drug.

MNKD : 5.71 (-0.17%)
LQDA : 11.08 (+0.82%)
UTHR : 329.16 (+0.15%)
Liquidia Announces the Publication of Long-Term Clinical Data from Completed INSPIRE Study in the Journal Pulmonary Circulation

Evaluated doses of YUTREPIA™ (treprostinil) inhalation powder from 26.5 mcg to 212 mcg which are comparable to 3 to 24 breaths of nebulized Tyvaso® per...

LQDA : 11.08 (+0.82%)
Liquidia to Participate in Upcoming Investor Conferences

MORRISVILLE, N.C., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will be participating at the following...

LQDA : 11.08 (+0.82%)
Liquidia Corporation Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

MORRISVILLE, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced the grant of an inducement stock option...

LQDA : 11.08 (+0.82%)
Liquidia Corporation Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

MORRISVILLE, N.C., July 21, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that, in connection with the previously...

LQDA : 11.08 (+0.82%)

Business Summary

Liquidia Technologies, Inc. is a late-stage clinical biopharmaceutical company. It focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. The company's product candidate consists of LIQ861 for the treatment of...

See More

Key Turning Points

3rd Resistance Point 12.06
2nd Resistance Point 11.71
1st Resistance Point 11.39
Last Price 11.08
1st Support Level 10.72
2nd Support Level 10.37
3rd Support Level 10.06

See More

52-Week High 16.99
Fibonacci 61.8% 12.68
Fibonacci 50% 11.35
Last Price 11.08
Fibonacci 38.2% 10.02
52-Week Low 5.71

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar